The article focuses on the review of mechanisms and side effects of approved immunotherapies. It discusses the chimeric antigen receptor (CAR) therapy approved by the U.S. Food and Drug Administration (FDA) for hematologic malignancies, whereas cancer vaccines take advantage of the tumor-associated antigens.